{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:32:26Z","timestamp":1791919946092,"version":"4.3.4"},"reference-count":132,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["N0-AI-65306"],"award-info":[{"award-number":["N0-AI-65306"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["N0-AI-30025"],"award-info":[{"award-number":["N0-AI-30025"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN2722001100016I"],"award-info":[{"award-number":["HHSN2722001100016I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2SB1AI02396-06"],"award-info":[{"award-number":["2SB1AI02396-06"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The development of therapeutics for cytomegalovirus (CMV) infections, while progressing, has not matched the pace of new treatments of human immunodeficiency virus (HIV) infections; nevertheless, recent developments in the treatment of CMV infections have resulted in improved human health and perhaps will encourage the development of new therapeutic approaches. First, the deployment of ganciclovir and valganciclovir for both the prevention and treatment of CMV infections and disease in transplant recipients has been further improved with the licensure of the efficacious and less toxic letermovir. Regardless, late-onset CMV disease, specifically pneumonia, remains problematic. Second, the treatment of congenital CMV infections with valganciclovir has beneficially improved both hearing and neurologic outcomes, both fundamental advances for these children. In these pediatric studies, viral load was decreased but not eliminated. Thus, an important lesson learned from studies in both populations is the need for new antiviral agents and the necessity for combination therapies as has been shown to be beneficial in the treatment of HIV infections, among others. The development of monoclonal antibodies, sirtuins, and cyclopropovir may provide new treatment options.<\/jats:p>","DOI":"10.1093\/infdis\/jiz493","type":"journal-article","created":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T02:21:37Z","timestamp":1569637297000},"page":"S32-S44","source":"Crossref","is-referenced-by-count":58,"title":["Advances in the Development of Therapeutics for Cytomegalovirus Infections"],"prefix":"10.1093","volume":"221","author":[{"given":"Edward","family":"Acosta","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Bowlin","sequence":"first","affiliation":[{"name":"Microbiotix, Inc, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brooks","sequence":"first","affiliation":[{"name":"Microbiotix, Inc, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Chiang","sequence":"first","affiliation":[{"name":"Evrys Bio, LLC, Doylestown, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Hussein","sequence":"first","affiliation":[{"name":"Microbiotix, Inc, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kimberlin","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence M","family":"Kauvar","sequence":"first","affiliation":[{"name":"Trellis Bioscience, LLC, Redwood City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Leavitt","sequence":"first","affiliation":[{"name":"Merck, West Point, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Prichard","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Whitley","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"2020030507500731800_CIT0001","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMra050700","article-title":"Newborn hearing screening\u2014a silent revolution","volume":"354","author":"Morton","year":"2006","journal-title":"N Engl J Med"},{"key":"2020030507500731800_CIT0002","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0022-3476(97)70248-8","article-title":"Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infections","volume":"130","author":"Fowler","year":"1997","journal-title":"J Pediatr"},{"key":"2020030507500731800_CIT0003","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-3476(99)70328-8","article-title":"Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?","volume":"135","author":"Fowler","year":"1999","journal-title":"J Pediatr"},{"key":"2020030507500731800_CIT0004","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jcv.2005.09.016","article-title":"Congenital cytomegalovirus (CMV) infection and hearing deficit","volume":"35","author":"Fowler","year":"2006","journal-title":"J Clin Virol"},{"key":"2020030507500731800_CIT0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(74)92997-3","article-title":"Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero","volume":"1","author":"Elek","year":"1974","journal-title":"Lancet"},{"key":"2020030507500731800_CIT0006","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"key":"2020030507500731800_CIT0007","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/rmv.544","article-title":"New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection","volume":"17","author":"Dollard","year":"2007","journal-title":"Rev Med Virol"},{"key":"2020030507500731800_CIT0008","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \u201csilent\u201d global burden of congenital cytomegalovirus","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2020030507500731800_CIT0009","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/archpedi.1982.03970460032007","article-title":"Symptomatic congenital cytomegalovirus. Disorders of language, learning, and hearing","volume":"136","author":"Williamson","year":"1982","journal-title":"Am J Dis Child"},{"key":"2020030507500731800_CIT0010","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1055\/s-0042-1748054","article-title":"Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus","volume":"11","author":"Dahle","year":"2000","journal-title":"J Am Acad Audiol"},{"key":"2020030507500731800_CIT0011","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1093\/cid\/cit629","article-title":"Congenital cytomegalovirus infection: clinical outcome","volume":"57","author":"Boppana","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020030507500731800_CIT0012","first-page":"35","article-title":"U.S. public health impact of congenital cytomegalovirus infection","volume":"41","author":"Centers for Disease Control and Prevention","year":"1992","journal-title":"MMWR Surveill Summ"},{"key":"2020030507500731800_CIT0013","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jpeds.2018.04.043","article-title":"Racial and ethnic differences in the prevalence of congenital cytomegalovirus infection","volume":"200","author":"Fowler","year":"2018","journal-title":"J Pediatr"},{"key":"2020030507500731800_CIT0014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcv.2007.09.004","article-title":"Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment","volume":"41","author":"Grosse","year":"2008","journal-title":"J Clin Virol"},{"key":"2020030507500731800_CIT0015","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJM199203053261010","article-title":"Congenital cytomegalovirus disease\u201420 years is long enough","volume":"326","author":"Yow","year":"1992","journal-title":"N Engl J Med"},{"key":"2020030507500731800_CIT0016","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1086\/421999","article-title":"Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee","volume":"39","author":"Arvin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020030507500731800_CIT0017","volume-title":"Bureau of Labor Statistics CPI inflation calculator","author":"US Department of Labor","year":"2015"},{"key":"2020030507500731800_CIT0018","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/rmv.1790","article-title":"Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?","volume":"24","author":"Cannon","year":"2014","journal-title":"Rev Med Virol"},{"key":"2020030507500731800_CIT0019","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1128\/AAC.40.9.2202","article-title":"Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group","volume":"40","author":"Zhou","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0020","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.clpt.6100150","article-title":"Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation","volume":"81","author":"Acosta","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2020030507500731800_CIT0021","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J Infect Dis"},{"key":"2020030507500731800_CIT0022","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med"},{"key":"2020030507500731800_CIT0023","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J Pediatr"},{"key":"2020030507500731800_CIT0024","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/516445","article-title":"Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group","volume":"175","author":"Whitley","year":"1997","journal-title":"J Infect Dis"},{"key":"2020030507500731800_CIT0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/clpt.1993.4","article-title":"Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group","volume":"53","author":"Trang","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"2020030507500731800_CIT0026","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jcv.2009.08.012","article-title":"Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system","volume":"46","author":"Oliver","year":"2009","journal-title":"J Clin Virol"},{"key":"2020030507500731800_CIT0027","volume-title":"Valganciclovir package insert","author":"Genentech."},{"key":"2020030507500731800_CIT0028","first-page":"317","article-title":"Cytomegalovirus infection","volume-title":"Red Book: 2015 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2015","edition":"30th ed"},{"key":"2020030507500731800_CIT0029","first-page":"310","article-title":"Cytomegalovirus infection","volume-title":"Red Book: 2018 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2018","edition":"31st ed"},{"key":"2020030507500731800_CIT0030","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/infdis\/jiy695","article-title":"Blood viral load in symptomatic congenital cytomegalovirus infection","volume":"219","author":"Marsico","year":"2019;","journal-title":"J Infect Dis"},{"key":"2020030507500731800_CIT0031","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med"},{"key":"2020030507500731800_CIT0032","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2020030507500731800_CIT0033","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"2020030507500731800_CIT0034","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-017-0860-8","article-title":"Letermovir: first global approval","volume":"78","author":"Kim","year":"2018","journal-title":"Drugs"},{"key":"2020030507500731800_CIT0035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/JVI.72.1.717-725.1998","article-title":"Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product","volume":"72","author":"Underwood","year":"1998","journal-title":"J Virol"},{"key":"2020030507500731800_CIT0036","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1021\/jm00020a025","article-title":"Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles","volume":"38","author":"Townsend","year":"1995","journal-title":"J Med Chem"},{"key":"2020030507500731800_CIT0037","volume-title":"Benzimidazoled-ribonucleosides as antiviral agents that target HCMV terminase","author":"Drach","year":"2006"},{"key":"2020030507500731800_CIT0038","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1128\/AAC.46.2.478-486.2002","article-title":"Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus","volume":"46","author":"Krosky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0039","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/JVI.72.6.4721-4728.1998","article-title":"Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56","volume":"72","author":"Krosky","year":"1998","journal-title":"J Virol"},{"key":"2020030507500731800_CIT0040","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0041","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J Virol"},{"key":"2020030507500731800_CIT0042","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am J Transplant"},{"key":"2020030507500731800_CIT0043","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl Int"},{"key":"2020030507500731800_CIT0044","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/jcph.1094","article-title":"Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects","volume":"58","author":"Marshall","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2020030507500731800_CIT0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2020030507500731800_CIT0046","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"2020030507500731800_CIT0047","volume-title":"Maribavir: a promising new antiherpes therapeutic agent.","author":"Biron","year":"2006"},{"key":"2020030507500731800_CIT0048","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev Med Virol"},{"key":"2020030507500731800_CIT0049","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/AAC.46.8.2373-2380.2002","article-title":"Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication","volume":"46","author":"Koszalka","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0050","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1128\/AAC.46.9.2969-2976.2002","article-title":"Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding","volume":"46","author":"Lalezari","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0051","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1128\/AAC.50.4.1130-1135.2006","article-title":"Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults","volume":"50","author":"Ma","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0052","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2020030507500731800_CIT0053","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"2020030507500731800_CIT0054","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0166-3542(02)00094-3","article-title":"Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus","volume":"56","author":"Evers","year":"2002","journal-title":"Antiviral Res"},{"key":"2020030507500731800_CIT0055","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1128\/AAC.00571-11","article-title":"Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase","volume":"55","author":"James","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0056","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0057","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"2020030507500731800_CIT0058","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3851\/IMP2533","article-title":"Selective anti-herpesvirus agents","volume":"23","author":"De Clercq","year":"2013","journal-title":"Antivir Chem Chemother"},{"key":"2020030507500731800_CIT0059","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0060","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro","volume":"49","author":"Williams-Aziz","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0061","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1128\/AAC.48.5.1869-1871.2004","article-title":"Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro","volume":"48","author":"Keith","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0062","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J Infect Dis"},{"key":"2020030507500731800_CIT0063","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1128\/AAC.50.4.1564-1566.2006","article-title":"Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro","volume":"50","author":"Randhawa","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0064","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antiviral Res"},{"key":"2020030507500731800_CIT0065","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/FTD.0000000000000353","article-title":"Brincidofovir is not a substrate for the human organic anion transporter 1: a mechanistic explanation for the lack of nephrotoxicity observed in clinical studies","volume":"38","author":"Tippin","year":"2016","journal-title":"Ther Drug Monit"},{"key":"2020030507500731800_CIT0066","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antiviral Res"},{"key":"2020030507500731800_CIT0067","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"2020030507500731800_CIT0068"},{"key":"2020030507500731800_CIT0069","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1081\/NCN-200059772","article-title":"Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines","volume":"24","author":"De Clercq","year":"2005","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2020030507500731800_CIT0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/rmv.354","article-title":"Non-nucleoside inhibitors of herpesviruses","volume":"12","author":"Wathen","year":"2002","journal-title":"Rev Med Virol"},{"key":"2020030507500731800_CIT0071","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0166-3542(01)00208-X","article-title":"Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses","volume":"54","author":"Brideau","year":"2002","journal-title":"Antiviral Res"},{"key":"2020030507500731800_CIT0072","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1128\/AAC.46.3.724-730.2002","article-title":"Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors","volume":"46","author":"Oien","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0073","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2004.10.003","article-title":"Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity","volume":"65","author":"Hartline","year":"2005","journal-title":"Antiviral Res"},{"key":"2020030507500731800_CIT0074","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.48.5.1647-1651.2004","article-title":"Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus","volume":"48","author":"Underwood","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0075","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1128\/AAC.48.5.1749-1755.2004","article-title":"Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0076","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","article-title":"In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses","volume":"47","author":"Williams","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0077","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.02311-13","article-title":"Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells","volume":"58","author":"Gentry","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0077a","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/AAC.00717-19","article-title":"Hart M, et al. Phase IB trial to evaluate the safety and pharmacokinetics of multiple ascending doses of filociclovir (MBX-400, Cyclopropavir) in healthy volunteers","volume":"63","author":"Rouphael","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0078","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"key":"2020030507500731800_CIT0079","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.01259-10","article-title":"Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility","volume":"55","author":"Chou","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0080","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1128\/AAC.00468-10","article-title":"Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir","volume":"54","author":"Gentry","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0081","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0002-9378(97)80043-9","article-title":"Clinical uses of intravenous immunoglobulin in pregnancy","volume":"176","author":"Clark","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"2020030507500731800_CIT0082","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/cis425","article-title":"Primary maternal cytomegalovirus infection during pregnancy: do we have a treatment option?","volume":"55","author":"Adler","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020030507500731800_CIT0083","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/uog.19164","article-title":"Prevention\u2009of\u2009maternal-fetal\u2009transmission\u2009of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration","volume":"53","author":"Kagan","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2020030507500731800_CIT0084","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-0012.2007.00750.x","article-title":"CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis","volume":"22","author":"Bonaros","year":"2008","journal-title":"Clin Transplant"},{"key":"2020030507500731800_CIT0085","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26420","article-title":"The role of immunoglobulin prophylaxis for prevention of cytomegalovirus infection in pediatric hematopoietic stem cell transplantation recipients","volume":"64","author":"Goldstein","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"2020030507500731800_CIT0086","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J Virol"},{"key":"2020030507500731800_CIT0087","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01794-16","article-title":"Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients","volume":"61","author":"Ishida","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0088","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"2020030507500731800_CIT0089","doi-asserted-by":"crossref","first-page":"e1001256","DOI":"10.1371\/journal.ppat.1001256","article-title":"HCMV spread and cell tropism are determined by distinct virus populations","volume":"7","author":"Scrivano","year":"2011","journal-title":"PLoS Pathog"},{"key":"2020030507500731800_CIT0090","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"2020030507500731800_CIT0091","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00382-16","article-title":"In vitro characterization of human cytomegalovirus-targeting therapeutic monoclonal antibodies LJP538 and LJP539","volume":"60","author":"Patel","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0092","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123982","article-title":"A native human monoclonal antibody targeting HCMV gB (AD-2 site I)","volume":"19","author":"McVoy","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2020030507500731800_CIT0093","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2353\/ajpath.2006.050482","article-title":"Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis","volume":"168","author":"Maidji","year":"2006","journal-title":"Am J Pathol"},{"key":"2020030507500731800_CIT0094","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/viro.2002.1752","article-title":"Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus","volume":"305","author":"Lantto","year":"2003","journal-title":"Virology"},{"key":"2020030507500731800_CIT0095","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/infdis\/jiw487","article-title":"Maternal antibody responses and nonprimary congenital cytomegalovirus infection of HIV-1-exposed infants","volume":"214","author":"Bialas","year":"2016","journal-title":"J Infect Dis"},{"key":"2020030507500731800_CIT0096","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1128\/AAC.04295-14","article-title":"A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types","volume":"59","author":"Kauvar","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0097","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.placenta.2017.04.020","article-title":"Congenital cytomegalovirus infection undermines early development and functions of the human placenta","volume":"59(Suppl 1)","author":"Pereira","year":"2017","journal-title":"Placenta"},{"key":"2020030507500731800_CIT0098","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01650-16","article-title":"Impact of antibodies and strain polymorphisms on cytomegalovirus entry and spread in fibroblasts and epithelial cells","volume":"91","author":"Cui","year":"2017","journal-title":"J Virol"},{"key":"2020030507500731800_CIT0099","doi-asserted-by":"crossref","first-page":"e1001344","DOI":"10.1371\/journal.ppat.1001344","article-title":"Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants","volume":"7","author":"Renzette","year":"2011","journal-title":"PLoS Pathog"},{"key":"2020030507500731800_CIT0100","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/MOT.0000000000000541","article-title":"Drug-resistant cytomegalovirus: clinical implications of specific mutations","volume":"23","author":"Razonable","year":"2018","journal-title":"Curr Opin Organ Transplant"},{"key":"2020030507500731800_CIT0101","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0102","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500731800_CIT0103","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jmv.24659","article-title":"Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses","volume":"89","author":"Hayes","year":"2017","journal-title":"J Med Virol"},{"key":"2020030507500731800_CIT0104","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev-biochem-060815-014537","article-title":"The substrate specificity of sirtuins","volume":"85","author":"Bheda","year":"2016","journal-title":"Annu Rev Biochem"},{"key":"2020030507500731800_CIT0105","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.cell.2014.11.046","article-title":"Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity","volume":"159","author":"Mathias","year":"2014","journal-title":"Cell"},{"key":"2020030507500731800_CIT0106","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cmet.2017.03.003","article-title":"SIRT4 is a lysine deacylase that controls leucine metabolism and insulin secretion","volume":"25","author":"Anderson","year":"2017","journal-title":"Cell Metab"},{"key":"2020030507500731800_CIT0107","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrm.2016.140","article-title":"Metabolic regulation of gene expression through histone acylations","volume":"18","author":"Sabari","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2020030507500731800_CIT0108","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.cellsig.2013.06.007","article-title":"Antagonistic crosstalk between NF-\u03baB and SIRT1 in the regulation of inflammation and metabolic disorders","volume":"25","author":"Kauppinen","year":"2013","journal-title":"Cell Signal"},{"key":"2020030507500731800_CIT0109","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02249-14","article-title":"Sirtuins are evolutionarily conserved viral restriction factors","volume":"5","author":"Koyuncu","year":"2014","journal-title":"mBio"},{"key":"2020030507500731800_CIT0110","doi-asserted-by":"crossref","first-page":"e1007437","DOI":"10.1371\/journal.ppat.1007437","article-title":"Salmonella escapes adaptive immune response via SIRT2 mediated modulation of innate immune response in dendritic cells","volume":"14","author":"Gogoi","year":"2018","journal-title":"PLoS Pathog"},{"key":"2020030507500731800_CIT0111","doi-asserted-by":"crossref","first-page":"1238858","DOI":"10.1126\/science.1238858","article-title":"A role for SIRT2-dependent histone H3K18 deacetylation in bacterial infection","volume":"341","author":"Eskandarian","year":"2013","journal-title":"Science"},{"key":"2020030507500731800_CIT0112","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.celrep.2018.03.116","article-title":"Infection reveals a modification of SIRT2 critical for chromatin association","volume":"23","author":"Pereira","year":"2018","journal-title":"Cell Rep"},{"key":"2020030507500731800_CIT0113","doi-asserted-by":"crossref","first-page":"e1004684","DOI":"10.1371\/journal.ppat.1004684","article-title":"Leishmania infantum modulates host macrophage mitochondrial metabolism by hijacking the SIRT1-AMPK axis","volume":"11","author":"Moreira","year":"2015","journal-title":"PLoS Pathog"},{"key":"2020030507500731800_CIT0114","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1128\/JVI.00219-14","article-title":"Activation of Kaposi\u2019s sarcoma-associated herpesvirus (KSHV) by inhibitors of class III histone deacetylases: identification of sirtuin 1 as a regulator of the KSHV life cycle","volume":"88","author":"Li","year":"2014","journal-title":"J Virol"},{"key":"2020030507500731800_CIT0115","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2174\/1389450111314060005","article-title":"Sirtuin-1 and HIV-1: an overview","volume":"14","author":"Pinzone","year":"2013","journal-title":"Curr Drug Targets"},{"key":"2020030507500731800_CIT0116","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.bbrc.2018.01.127","article-title":"HBx-elevated SIRT2 promotes HBV replication and hepatocarcinogenesis","volume":"496","author":"Cheng","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"2020030507500731800_CIT0117","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00955-18","article-title":"Sirtuin 2 isoform 1 enhances hepatitis B virus RNA transcription and DNA synthesis through the AKT\/GSK-3beta\/beta-catenin signaling pathway","volume":"92","author":"Piracha","year":"2018","journal-title":"J Virol"},{"key":"2020030507500731800_CIT0118"},{"key":"2020030507500731800_CIT0119","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1128\/JVI.00694-10","article-title":"Viral mutation rates","volume":"84","author":"Sanju\u00e1n","year":"2010","journal-title":"J Virol"},{"key":"2020030507500731800_CIT0120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"2020030507500731800_CIT0121","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01802-16","article-title":"Inclusion body fusion of human parainfluenza virus type 3 regulated by acetylated alpha-tubulin enhances viral replication","volume":"91","author":"Zhang","year":"2017","journal-title":"J Virol"},{"key":"2020030507500731800_CIT0122","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-virology-031413-085425","article-title":"Human cytomegalovirus: coordinating cellular stress, signaling, and metabolic pathways","volume":"1","author":"Shenk","year":"2014","journal-title":"Annu Rev Virol"},{"key":"2020030507500731800_CIT0123","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1074\/jbc.M113.487736","article-title":"A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer","volume":"289","author":"Hoffmann","year":"2014","journal-title":"J Biol Chem"},{"key":"2020030507500731800_CIT0124","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-09-0971","article-title":"SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2","volume":"9","author":"Peck","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2020030507500731800_CIT0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/viro.1996.0516","article-title":"Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1","volume":"224","author":"Bresnahan","year":"1996","journal-title":"Virology"},{"key":"2020030507500731800_CIT0126","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1128\/JVI.69.11.6697-6704.1995","article-title":"Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest","volume":"69","author":"Jault","year":"1995","journal-title":"J Virol"},{"key":"2020030507500731800_CIT0127","doi-asserted-by":"crossref","first-page":"13546","DOI":"10.1073\/pnas.1301463110","article-title":"SIRT2 directs the replication stress response through CDK9 deacetylation","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020030507500731800_CIT0128","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1074\/jbc.M113.537266","article-title":"Sirt2 deacetylase is a novel AKT binding partner critical for AKT activation by insulin","volume":"289","author":"Ramakrishnan","year":"2014","journal-title":"J Biol Chem"},{"key":"2020030507500731800_CIT0129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.2011.055236","article-title":"The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells","volume":"97","author":"Dan","year":"2012","journal-title":"Haematologica"},{"key":"2020030507500731800_CIT0130","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1172\/JCI73805","article-title":"CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses","volume":"124","author":"Yamamoto","year":"2014","journal-title":"J Clin Invest"},{"key":"2020030507500731800_CIT0131","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.antiviral.2018.07.015","article-title":"Aberrant regulation of the Akt signaling network by human cytomegalovirus allows for targeting of infected monocytes","volume":"158","author":"Peppenelli","year":"2018","journal-title":"Antiviral Res"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/Supplement_1\/S32\/32791360\/jiz493.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/Supplement_1\/S32\/32791360\/jiz493.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T05:22:04Z","timestamp":1721798524000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/Supplement_1\/S32\/5781906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":132,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2020,3,5]]},"published-print":{"date-parts":[[2020,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz493","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,15]]},"published":{"date-parts":[[2020,3,5]]}}}